Considerable progress has been made to explain the aetiology of intrahepatic cholestasis of pregnancy (ICP) and of the adverse pregnancy outcomes associated with high maternal total serum bile acids (TSBAs). The reported thresholds for non-fasting TSBA associated with the risk of stillbirth and spontaneous preterm birth can be used to identify pregnancies at risk of these adverse outcomes to decide on appropriate interventions and to give reassurance to women with lower concentrations of TSBA. Data also support the use of ursodeoxycholic acid to protect against the risk of spontaneous preterm birth. A previous history of ICP may be associated with higher rates of subsequent hepatobiliary disease: if there is a suspicion of underlying susceptibility, clinicians caring for women with ICP should screen for associated disorders or for genetic susceptibility and, where appropriate, refer for ongoing hepatology review.
GeenesVWilliamsonC. Intrahepatic cholestasis of pregnancy. World J Gastroenterol2009; 15: 2049–2066.
2.
ChenYZhangHNingW, et al.The impact of intrahepatic cholestasis on pregnancy outcomes: a retrospective cohort study. BMC Gastroenterol2023; 23: 16.
3.
ElorantaMLElorantaM-LHeinonenS, et al.Risk of obstetric cholestasis in sisters of index patients. Clin Genet2001; 60: 42–45.
4.
ReyesHBáezMEGonzálezMC, et al.Selenium, zinc and copper plasma levels in intrahepatic cholestasis of pregnancy, in normal pregnancies and in healthy individuals, in Chile. J Hepatol2000; 32: 542–549.
5.
DixonPHSambrottaMChambersJ, et al.An expanded role for heterozygous mutations of ABCB4, ABCB11, ATP8B1, ABCC2 and TJP2 in intrahepatic cholestasis of pregnancy. Sci Rep2017; 7: 11823.
6.
AhlfeldF. Berichte und Arbeiten aus der Geburtshulflich-Gynaekologischen Klinik zu Giessen, 1881–1882. Leipzig: Grunow, 1883, p.148.
7.
SvanborgAOhlssonS. Recurrent jaundice of pregnancy; a clinical study of twenty-two cases. Am J Med1959; 27: 40–49.
8.
ThorlingL. Jaundice in pregnancy; a clinical study. Acta Med Scand Suppl1955; 302: 1–123.
KenyonAPPiercyCNGirlingJ, et al.Pruritus may precede abnormal liver function tests in pregnant women with obstetric cholestasis: a longitudinal analysis. BJOG2001; 108: 1190–1192.
11.
OvadiaCSeedPTSklavounosA, et al.Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers: results of aggregate and individual patient data meta-analyses. Lancet2019; 393: 899–909.
12.
MitchellALOvadiaCSyngelakiA, et al.Re-evaluating diagnostic thresholds for intrahepatic cholestasis of pregnancy: case-control and cohort study. BJOG2021; 128: 1635–1644.
13.
European Association for the Study of the LiverEASL Clinical Practice Guidelines on the management of liver diseases in pregnancy. J Hepatol2023; 79: 768–828.
14.
MarkusCCoatSMarschallH-U, et al.The BACH project protocol: an international multicentre total bile acid comparison and harmonisation project and sub-study of the TURRIFIC randomised trial. Clin Chem Laboratory Med (CCLM)2021; 59: 1921–1929.
15.
OedaSTakahashiHYoshidaH, et al.Prevalence of pruritus in patients with chronic liver disease: a multicenter study. Hepatol Res2018; 48: E252–E262.
16.
KushnerTLangeMArgiriadiPA, et al.Prevalence, risk profiles, and national implications of nonalcoholic fatty liver disease in pregnant individuals. Clin Gastroenterol Hepatol2024; 22: 194–196.e1.
17.
RodaARodaESamaC, et al.Serum primary bile acids in Gilbert's syndrome. Gastroenterology1982; 82: 77–83.
18.
ZeichnerJA. Narrowband UV-B phototherapy for the treatment of Acne Vulgaris during pregnancy. Arch Dermatol2011; 147: 537–539.
19.
ParkKKMuraseJE. Narrowband UV-B phototherapy during pregnancy and folic acid depletion. Arch Dermatol2012; 148: 132–133.
20.
BeuersUWoltersFOude ElferinkRPJ. Mechanisms of pruritus in cholestasis: understanding and treating the itch. Nat Rev Gastroenterol Hepatol2023; 20: 26–36.
21.
HeerkensMDeddenSScheepersH, et al.Effect of plasmapheresis on cholestatic pruritus and autotaxin activity during pregnancy. Hepatology2019; 69: 2707–2710.
22.
StapelbroekJMvan ErpecumKJKlompLWJ, et al.Nasobiliary drainage induces long-lasting remission in benign recurrent intrahepatic cholestasis. Hepatology2006; 43: 51–53.
HegadeVSKrawczykMKremerAE, et al.The safety and efficacy of nasobiliary drainage in the treatment of refractory cholestatic pruritus: a multicentre European study. Aliment Pharmacol Ther2016; 43: 294–302.
25.
GuthrieGStollBChackoS, et al.Rifampicin, not vitamin E, suppresses parenteral nutrition-associated liver disease development through the pregnane X receptor pathway in piglets. Am J Physiol Gastrointest Liver Physiol2020; 318: G41–g52.
26.
OsbornECWoottonIDPDa SilvaLC, et al.Serum-bile-acid levels in liver disease. Lancet1959; 2: 1049–1053.
27.
KremerAEMartensJJWWKulikW, et al.Lysophosphatidic acid is a potential mediator of cholestatic pruritus. Gastroenterology2010; 139: 1008–18–1018 e1.
28.
KremerAEvan DijkRLeckieP, et al.Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions. Hepatology2012; 56: 1391–1400.
29.
KremerAEBolierRDixonPH, et al.Autotaxin activity has a high accuracy to diagnose intrahepatic cholestasis of pregnancy. J Hepatol2015; 62: 897–904.
30.
GlantzAReillyS-JBenthinL, et al.Intrahepatic cholestasis of pregnancy: amelioration of pruritus by UDCA is associated with decreased progesterone disulphates in urine. Hepatology2008; 47: 544–551.
31.
Abu-HayyehSOvadiaCLieuT, et al.Prognostic and mechanistic potential of progesterone sulfates in intrahepatic cholestasis of pregnancy and pruritus gravidarum. Hepatology2016; 63: 1287–1298.
32.
AlemiFKwonEPooleDP, et al.The TGR5 receptor mediates bile acid-induced itch and analgesia. J Clin Invest2013; 123: 1513–1530.
33.
YuHZhaoTLiuS, et al.MRGPRX4 is a bile acid receptor for human cholestatic itch. Elife2019; 8: 48431.
34.
de VriesEBeuersU. Ursodeoxycholic acid in pregnancy?J Hepatol2019; 71: 1237–1245.
35.
BeuersUNathansonMHIsalesCM,et al.Tauroursodeoxycholic acid stimulates hepatocellular exocytosis and mobilizes extracellular ca++ mechanisms defective in cholestasis. J Clin Invest1993; 92: 2984–2993.
36.
BeuersU, et al.Tauroursodeoxycholic acid inserts the apical conjugate export pump, Mrp2, into canalicular membranes and stimulates organic anion secretion by protein kinase C-dependent mechanisms in cholestatic rat liver. Hepatology2001; 33: 1206–1216.
37.
KondrackieneJBeuersUKupcinskasL. Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy. Gastroenterology2005; 129: 894–901.
38.
ChazouilleresOBeuersUBergquistA, et al.EASL Clinical practice guidelines on sclerosing cholangitis. J Hepatol2022; 77: 761–806.
39.
de VriesEBolierRGoetJ, et al.Fibrates for itch (FITCH) in fibrosing cholangiopathies: a double-blind, randomized, placebo-controlled trial. Gastroenterology2021; 160: 734–743.e6.
40.
ForgetEJMenziesD. Adverse reactions to first-line antituberculosis drugs. Expert Opin Drug Saf2006; 5: 231–249.
41.
De VrieseASRobbrechtDLVanholderRC, et al.Rifampicin-associated acute renal failure: pathophysiologic, immunologic, and clinical features. Am J Kidney Dis1998; 31: 108–115.
42.
SousaGCarreiroADuarteP. Rifampicin-induced disseminated intravascular coagulation: an antibody-mediated side effect. Pulmonology2021; 27: 269–272.
43.
SveroniDStefosARigopoulouEI, et al.Rifampicin: not always an innocent drug. BMJ Case Rep2018; 11: e227356.
44.
HeinzNVittorioJ. Treatment of cholestasis in infants and young children. Curr Gastroenterol Rep2023; 25: 344–354.
45.
OvadiaCPerdones-MonteroASpagouK, et al.Enhanced microbial bile acid deconjugation and impaired ileal uptake in pregnancy repress intestinal regulation of bile acid synthesis. Hepatology2019; 70: 276–293.
46.
BeuersUTraunerMJansenP, et al.New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond. J Hepatol2015; 62: S25–S37.
47.
NewmanLAMullerKRowlandA. Circulating cell-specific extracellular vesicles as biomarkers for the diagnosis and monitoring of chronic liver diseases. Cell Mol Life Sci2022; 79: 232.
48.
KrautkramerKAFanJBäckhedF. Gut microbial metabolites as multi-kingdom intermediates. Nat Rev Microbiol2020; 19: 77–94.
49.
NakamotoNSasakiNAokiR, et al.Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis. Nat Microbiol2019; 4: 492–503.
50.
KirbasABiberogluEErsoyAO, et al.The role of interleukin-17 in intrahepatic cholestasis of pregnancy. J Matern Fetal Neonatal Med2016; 29: 977–981.
51.
KorenOGoodrichJCullenderT, et al.Host remodeling of the gut microbiome and metabolic changes during pregnancy. Cell2012; 150: 470–480.
52.
OvadiaCPerdones-MonteroAFanHM, et al.Ursodeoxycholic acid enriches intestinal bile salt hydrolase-expressing Bacteroidetes in cholestatic pregnancy. Sci Rep2020; 10: 3895.
53.
Wikström ShemerEMarschallHULudvigssonJF,et al.Intrahepatic cholestasis of pregnancy and associated adverse pregnancy and fetal outcomes: a 12-year population-based cohort study. BJOG: An Int J Obs Gynaecol2013; 120: 717–723.
54.
MaratheJALimWHMetzMP, et al.A retrospective cohort review of intrahepatic cholestasis of pregnancy in a South Australian population. Eur J Obstet Gynecol Reprod Biol2017; 218: 33–38.
55.
MartineauMRakerCPowrieR, et al.Intrahepatic cholestasis of pregnancy is associated with an increased risk of gestational diabetes. Eur J Obstet Gynecol Reprod Biol2014; 176: 80–85.
56.
WijarnpreechaKThongprayoonCSanguankeoA, et al.Hepatitis C infection and intrahepatic cholestasis of pregnancy: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol2017; 41: 39–45.
57.
WalkerKFChappellLCHagueWM, et al.Pharmacological interventions for treating intrahepatic cholestasis of pregnancy. Cochrane Database Syst Rev2020; 7: CD000493.
58.
ChappellLCBellJLSmithA, et al.Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial. Lancet2019; 394: 849–860.
59.
OvadiaCSajousJSeedPT, et al.Ursodeoxycholic acid in intrahepatic cholestasis of pregnancy: a systematic review and individual participant data meta-analysis. Lancet Gastroenterol Hepatol2021; 6: 547–558.
60.
HagueWMCallawayLChambersJ, et al.A multi-centre, open label, randomised, parallel-group, superiority trial to compare the efficacy of URsodeoxycholic acid with RIFampicin in the management of women with severe early onset intrahepatic cholestasis of pregnancy: the TURRIFIC randomised trial. BMC Pregnancy Childbirth2021; 21: 51.
61.
European Association for the Study of the Liver. EASL. Clinical practice guidelines: management of cholestatic liver diseases. J Hepatol2009; 51: 237–267.
62.
Ribes BautistaCRossich VerdésRAramburo CaragolA, et al.Life-threatening hemorrhage in the neonate of a rifampicin-treated mother. An Pediatr (Barc)2006; 65: 629–630.
63.
FaradonbehFASaIILastuvkovaH, et al.Metformin impairs bile acid homeostasis in ethinylestradiol-induced cholestasis in mice. Chem-Biol Interact2021; 345: 109525.
LammertFMarschallH-UGlantzA, et al.Intrahepatic cholestasis of pregnancy: molecular pathogenesis, diagnosis and management. J Hepatol2000; 33: 1012–1021.
66.
Wikström ShemerEAStephanssonOThuressonM, et al.Intrahepatic cholestasis of pregnancy and cancer, immune-mediated and cardiovascular diseases: a population-based cohort study. J Hepatol2015; 63: 456–461.
67.
HuangLLiXLiuT, et al.Effect of intrahepatic cholestasis of pregnancy on infantile food allergy: a retrospective longitudinal study cohort in Southwest China. Eur J Obstet Gynecol Reprod Biol2022; 272: 110–115.
68.
PapacleovoulouGAbu-HayyehSNikolopoulouE, et al.Maternal cholestasis during pregnancy programs metabolic disease in offspring. J Clin Invest2013; 123(7): 3172–3181.
69.
ChenSAhlqvistVHSjöqvistH, et al.Maternal intrahepatic cholestasis of pregnancy and neurodevelopmental conditions in offspring: a population-based cohort study of 2 million Swedish children. PLoS Med2024; 21: e1004331.
